Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 8:13 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 840 matching trials from the live ClinicalTrials.gov search.
Conditions
Acute Leukemia, Myelodysplastic Syndromes
Interventions
Interferon gamma (IFNγ)-primed human bone marrow-derived mesenchymal stromal cells
Drug
Lead sponsor
Edwin Horwitz
Other
Eligibility
1 Year and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
3
States / cities
Atlanta, Georgia
Conditions
Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Lung Carcinoma, Malignant Digestive System Neoplasm, Malignant Solid Neoplasm
Interventions
Computer-Assisted Intervention, Patient Monitoring, Questionnaire Administration
Other · Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Conditions
Lymphoma
Interventions
IV Busulfan, Cyclophosphamide and Etoposide (BuCyE Regimen)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Berkeley, California + 30 more
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
6 Minute Walk Functional Test, Behavioral Intervention, Survey Administration, Timed Get Up and Go Test
Other · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
6 Years to 29 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
2
States / cities
Dallas, Texas • Houston, Texas
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Pneumonia, Pneumonitis, Severe Acute Respiratory Distress Syndrome, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Tocilizumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
2 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
5
States / cities
Rockville, Maryland • Las Vegas, Nevada • Oklahoma City, Oklahoma + 1 more
Conditions
Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Myelodysplastic Syndrome, Myelodysplastic Syndrome With Excess Blasts
Interventions
Dilanubicel, Cyclophosphamide, Fludarabine, Thiotepa, Total-Body Irradiation, Umbilical Cord Blood Transplantation, Laboratory Biomarker Analysis, Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy, Multigated Acquisition Scan, Electrocardiography, Computed Tomography
Biological · Drug · Radiation + 2 more
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
10 Years to 65 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Seattle, Washington
Conditions
Cancer
Interventions
itraconazole, voriconazole
Drug
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
12 Years to 120 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2003
U.S. locations
1
States / cities
Los Angeles, California
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm
Interventions
Tagraxofusp-erzs
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
2 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Chronic Graft Versus Host Disease, Hematopoietic and Lymphatic System Neoplasm, Malignant Solid Neoplasm
Interventions
Biospecimen Collection, Mindfulness Relaxation, Survey Administration
Procedure · Behavioral · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
Duarte, California
Conditions
Acute Lymphoblastic Leukemia, Acute Myelocytic Leukemia, Chronic Myelocytic Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome, Hodgkin or Non-Hodgkin Lymphoma, Sarcoma, Myeloid
Interventions
clofarabine, cytarabine, busulfan, Plerixafor, cyclophosphamide, antithymocyte globulin (rabbit), stem cells, Tacrolimus, mycophenolate mofetil
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Interview, Survey Administration
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Conditions
Acute Lymphoblastic Leukemias, Acute Myelocytic Leukemia, Chronic Myeloid Leukemia, Juvenile Myelomonocytic Leukemia, Myelodysplastic Syndrome, Hemoglobinuria, Paroxysmal, Non-Hodgkin Lymphoma
Interventions
Allogeneic Stem Cell Transplantation, Chemotherapy and antibodies
Procedure · Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
2 Years to 21 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
1
States / cities
Memphis, Tennessee
Conditions
Breast Carcinoma, Esophageal Carcinoma, Genitourinary System Carcinoma, Head and Neck Carcinoma, Hematopoietic and Lymphoid Cell Neoplasm, Lung Carcinoma, Malignant Central Nervous System Neoplasm, Malignant Digestive System Neoplasm, Malignant Solid Neoplasm
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
5,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Behavioral Intervention, Electronic Health Record Review, Quality-of-Life Assessment, Questionnaire Administration
Behavioral · Other
Lead sponsor
University of Rochester NCORP Research Base
Other
Eligibility
18 Years and older
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
153
States / cities
Kingman, Arizona • Fort Smith, Arkansas • Denver, Colorado + 102 more
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Hodgkin Lymphoma, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma
Interventions
Letermovir, Multi-peptide CMV-Modified Vaccinia Ankara Vaccine, Placebo Administration
Drug · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2030
U.S. locations
1
States / cities
Duarte, California
Conditions
Allogeneic Hematopoietic Stem Cell Transplant Recipient, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Recombinant Human Papillomavirus Nonavalent Vaccine
Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
COVID-19 Infection, COVID-19-Associated Acute Respiratory Distress Syndrome, Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm, Symptomatic COVID-19 Infection Laboratory-Confirmed
Interventions
Best Practice, Mesenchymal Stem Cell
Other · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Data Capture, Electronic Medical Record
Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Houston, Texas
Conditions
Hematopoietic and Lymphatic System Neoplasm, Histiocytic Sarcoma, Malignant Histiocytosis, Peripheral T-Cell Lymphoma, Not Otherwise Specified, Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Follicular Lymphoma, Recurrent Langerhans Cell Histiocytosis, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelofibrosis, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Refractory Erdheim-Chester Disease, Refractory Follicular Lymphoma, Refractory Langerhans Cell Histiocytosis, Refractory Lymphoplasmacytic Lymphoma, Refractory Myelodysplastic Syndrome, Refractory Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Refractory Waldenstrom Macroglobulinemia, Rosai-Dorfman-Destombes Disease, Primary Central Nervous System Lymphoma, Recurrent Blastic Plasmacytoid Dendritic Cell Neoplasm, Recurrent Erdheim-Chester Disease, Recurrent Fibroblastic Reticular Cell Sarcoma, Recurrent Histiocytic Sarcoma, Recurrent Interdigitating Dendritic Cell Sarcoma, Recurrent Rosai-Dorfman-Destombes Disease, Refractory Blastic Plasmacytoid Dendritic Cell Neoplasm, Refractory Fibroblastic Reticular Cell Sarcoma, Refractory Histiocytic Sarcoma, Refractory Interdigitating Dendritic Cell Sarcoma, Refractory Rosai-Dorfman-Destombes Disease
Interventions
Axl/Mer/CSF1R Inhibitor Q702, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Survey Administration
Drug · Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Scottsdale, Arizona • Rochester, Minnesota
Conditions
Leukemia, Lymphoma, Myelodysplastic Syndromes
Interventions
HPC, Cord Blood
Biological
Lead sponsor
National Marrow Donor Program
Other
Eligibility
Female only
Enrollment
3,621 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2000 – 2011
U.S. locations
19
States / cities
Covina, California • Orange, California • San Diego, California + 16 more
Conditions
Advanced Malignant Solid Neoplasm, Anorexia, Hematopoietic and Lymphoid Cell Neoplasm
Interventions
Olanzapine, Megestrol Acetate, Questionnaire Administration
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
293
States / cities
Gilbert, Arizona • Goodyear, Arizona • Peoria, Arizona + 239 more
Conditions
Advanced Malignant Solid Neoplasm, Advanced Microsatellite Stable Colorectal Carcinoma, Hematopoietic and Lymphatic System Neoplasm, Metastatic Malignant Solid Neoplasm, Metastatic Microsatellite Stable Colorectal Carcinoma, Stage III Colorectal Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8
Interventions
Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Temozolomide, Tuvusertib
Procedure · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
23
States / cities
Irvine, California • La Jolla, California • Orange, California + 17 more
Active, not recruiting Phase 2 Interventional Accepts healthy volunteers

Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

NCT03922724
Conditions
Peripheral T-cell Lymphomas, Lymphoproliferative Disorders, Immune System Diseases
Interventions
ATL-RIC, mRIC, allo HCT, RIC, GVHD prophylaxis, IOC
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
12 Years to 120 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2030
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Conditions
COVID-19 Infection, Hematopoietic and Lymphoid System Neoplasm, Leukemia, Lymphoma, Plasma Cell Myeloma
Interventions
COVID-19 Vaccine, Diagnostic Laboratory Biomarker Analysis, Synthetic MVA-based SARS-CoV-2 Vaccine GEO-CM04S1
Biological · Other
Lead sponsor
GeoVax, Inc.
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
6
States / cities
Duarte, California • Baltimore, Maryland • Worcester, Massachusetts + 3 more